Immunovant, Inc. (IMVT) Stock Price & Analysis
Immunovant, Inc. (IMVT) rose 2.63% to USD 31.61 as of June 10, 2026 at 00:45 UTC, according to Nexqual real-time market data.
IMVT last closed at USD 30.8; the session ranged USD 30.26–31.66 on volume of 1,681,667 shares. Market capitalization is $6.49B, with a 52-week range of USD 14.32–36.29 (NMS). Source: Nexqual, June 10, 2026 at 00:45 UTC.
Key Statistics (as of June 10, 2026 at 00:45 UTC)
| Price | USD 31.61 |
|---|---|
| Change | ▲ 2.63% (up) |
| Previous Close | USD 30.8 |
| Open | USD 31.42 |
| Day Range | USD 30.26 – 31.66 |
| 52-Week Range | USD 14.32 – 36.29 |
| Volume | 1,681,667 shares |
| Market Cap | $6.49B |
| Exchange | NMS |
Technical Analysis (IMVT)
Nexqual's technical model rates IMVT "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.84 (neutral) |
| vs SMA50 | Above (USD 28.69) |
| MACD | 0.88 (positive) |
Analyst Ratings (IMVT)
Wall Street analysts rate IMVT "Buy" based on 17 analysts, with a mean price target of USD 45.76 (range USD 24–66), per Nexqual as of June 10, 2026 at 00:45 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 45.76 |
| High Target | USD 66 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 13 / 5 / 0 |
Earnings (IMVT)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.48 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.67 vs est -0.63 ▼ miss |
| 2025-12-31 | USD -0.54 vs est -0.69 ▲ beat |
| 2025-09-30 | USD -0.65 vs est -0.73 ▲ beat |
| 2025-06-30 | USD -0.71 vs est -0.67 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Financials & Fundamentals (IMVT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -64.82% |
| Debt / Equity | 0.01 |
| Current Ratio | 9.09 |
| Total Cash | $902.11M |
| Total Debt | $72,000 |
| Free Cash Flow | $-234.28M |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Financial Health Score (IMVT)
Nexqual rates Immunovant, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:45 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $902M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$407M |
| Efficiency | Critical — ROE -65%, ROA -38.4% |
Ownership (IMVT)
| Insider Ownership | +56.75% |
|---|---|
| Institutional Ownership | +54.73% |
| Shares Outstanding | 205.31M |
| Float | 78.84M |
| Short % of Float | +21.16% |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Leadership (IMVT)
Immunovant, Inc. is led by Eric Venker M.D., Pharm.D. (age 38), CEO & Director, per Nexqual as of June 10, 2026 at 00:45 UTC.
| CEO & Director | Eric Venker M.D., Pharm.D. (age 38) |
|---|---|
| Chief Operating Officer | Melanie Gloria B.S.N. (age 47) |
| Chief Financial Officer | Tiago M. Girao (age 46) |
| Chief Technology Officer | Jay S. Stout M.S. (age 61) |
| Senior Vice President of Human Resources | Christine Blodgett |
Major Backers & Investors (IMVT)
Notable institutional backers of Immunovant, Inc. include FMR, LLC, Deep Track Capital, Lp, Fidelity, according to Nexqual as of June 10, 2026 at 00:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 8.25% |
| Deep Track Capital, Lp | 5.61% |
| Fidelity | 3.76% |
| Baker Bros. Advisors, LP | 2.66% |
| T. Rowe Price | 2.49% |
| TCG Crossover Management, LLC | 2.17% |
| Morgan Stanley | 1.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.25% |
| BlackRock | 4.13% |
| State Street | 3.61% |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
From Immunovant, Inc.'s Latest SEC 10-K Filing (filed 2026-05-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
- It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
- Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | USD 29.05 | ▲ 1.64% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:45 UTC. This page is informational and not investment advice.